East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Upadacitinib
Rinvoq
Routinely available
SMC (SMC2315)
29/03/2023

Indication

For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.

For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

15mg prolonged-release tablet

Comments

-

Link to Advice

SMC2315

Advice Published

08/02/2021

SMC Submission Type

Full

SMC Status

Restricted